207 patient avdoralimab late treatment RCT:68% higher mortality (p=0.13). RCT 207 hospitalized COVID-19 patients showing no significant benefit with avdoralimab, a C5a receptor (C5aR1) inhibitor, compared to placebo across three cohorts of patients with varying COVID-19 severity. Oct 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005683, https://c19p.org/carvelli
